Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C
Aim of investigation. To study efficacy and safety of domestic recombinant interferon α-2b Altevir® in combination to ribavirin in previously untreated patients with chronic hepatitis C (CHC).Material and methods. Retrospective treatment results rating of 85 patients (49 men (57%) and 36 women (43%)...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2014-08-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1104 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860234501750784 |
|---|---|
| author | N. B. Kovaleva |
| author_facet | N. B. Kovaleva |
| author_sort | N. B. Kovaleva |
| collection | DOAJ |
| description | Aim of investigation. To study efficacy and safety of domestic recombinant interferon α-2b Altevir® in combination to ribavirin in previously untreated patients with chronic hepatitis C (CHC).Material and methods. Retrospective treatment results rating of 85 patients (49 men (57%) and 36 women (43%)) was carried out. All patients received 3 million IU per day of Altevir® subcutaneously and ribavirin (Ribapeg). Treatment duration was 48 wks for patients with 1-st genotype of hepatitis C virus (HCV) and 24 wks — for patients with 2nd and 3а HCV genotypes. Results. Aviremia in 24 wks after the end of therapy (sustained virologic response — SVR) has been achieved in 100% of patients with 2-st HCV genotype, in 95,8% patients with 3а HCV genotype and in 65,6% patients with 1b HCV genotype. The registered adverse effects, well-known for interferon α-2b therapy, as a rule, were mild or moderate, AVT cancellation was not required in any patient.Conclusions. For patients with CHC with 2-st, 3а HCV genotypes and favorable prognosis of virologic response at combined AVT, including Altevir® and ribavirin, SVR frequency can reach 100 and 96% respectively. At AVT, including Altevir® and ribavirin to CHC patients with 1b genotype of HCV and favorable prognosis of virologic response, 66% SVR rate can be achieved. |
| format | Article |
| id | doaj-art-d4a8e827e95a4594af546981410dc774 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2014-08-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-d4a8e827e95a4594af546981410dc7742025-02-10T16:14:33ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732014-08-012426568705Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis CN. B. Kovaleva0State educational state-funded institution of higher professional education «Ural state medical university»Aim of investigation. To study efficacy and safety of domestic recombinant interferon α-2b Altevir® in combination to ribavirin in previously untreated patients with chronic hepatitis C (CHC).Material and methods. Retrospective treatment results rating of 85 patients (49 men (57%) and 36 women (43%)) was carried out. All patients received 3 million IU per day of Altevir® subcutaneously and ribavirin (Ribapeg). Treatment duration was 48 wks for patients with 1-st genotype of hepatitis C virus (HCV) and 24 wks — for patients with 2nd and 3а HCV genotypes. Results. Aviremia in 24 wks after the end of therapy (sustained virologic response — SVR) has been achieved in 100% of patients with 2-st HCV genotype, in 95,8% patients with 3а HCV genotype and in 65,6% patients with 1b HCV genotype. The registered adverse effects, well-known for interferon α-2b therapy, as a rule, were mild or moderate, AVT cancellation was not required in any patient.Conclusions. For patients with CHC with 2-st, 3а HCV genotypes and favorable prognosis of virologic response at combined AVT, including Altevir® and ribavirin, SVR frequency can reach 100 and 96% respectively. At AVT, including Altevir® and ribavirin to CHC patients with 1b genotype of HCV and favorable prognosis of virologic response, 66% SVR rate can be achieved.https://www.gastro-j.ru/jour/article/view/1104chronic hepatitis caltevir®treatment of chronic hepatitis cadverse effects |
| spellingShingle | N. B. Kovaleva Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C Российский журнал гастроэнтерологии, гепатологии, колопроктологии chronic hepatitis c altevir® treatment of chronic hepatitis c adverse effects |
| title | Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C |
| title_full | Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C |
| title_fullStr | Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C |
| title_full_unstemmed | Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C |
| title_short | Russian interferon <i>α</i>-2b drug in the treatment of chronic hepatitis C |
| title_sort | russian interferon i α i 2b drug in the treatment of chronic hepatitis c |
| topic | chronic hepatitis c altevir® treatment of chronic hepatitis c adverse effects |
| url | https://www.gastro-j.ru/jour/article/view/1104 |
| work_keys_str_mv | AT nbkovaleva russianinterferoniai2bdruginthetreatmentofchronichepatitisc |